Movers and SHAKERS
Potential Therapy for Pulmonary Fibrosis in COVID-19 Patients
Ceapro, Inc. is a publicly-held (TSX-V: CZO, OTCQX: CRPOF) Canadian biotechnology company developing and commercializing “active ingredients” for the healthcare and cosmetic industries. Ceapro’s active ingredients are primarily derived from oats and other renewable plant resources. The Company utilizes its proprietary plant extraction-based manufacturing process to supply active ingredients based on “oat beta glucan and avenanthramides”. Ceapro has patented a technology known as “Pressurized Gas eXpanded (PGX) technology”, which has superior features when compared to conventional drying and purification technologies. Using PGX technology, Ceapro generates novel biopolymers and biocomposites with micro/nanoparticles.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Ceapro expands collaboration with McMaster University. Under the new collaboration agreement, Ceapro will sponsor the development of an inhalable therapeutic based on “PGXprocessed yeast beta glucan” (PGX-YBG) for the treatment of pulmonary fibrosis in COVID19 patients. In preclinical models, PGX-YBG has shown immunomodulatory properties.
Versatility of Ceapro's proprietary PGX Technology. PGX technology utilizes the unique properties of a PGX liquid consisting of pressurized carbon dioxide and ethanol to dry aqueous polymer solutions at mild operating conditions in a spray chamber, which allows the production of ultra thin, high value biopolymers with multiple medical and...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.